Related Experiment Videos

Inclisiran for LDL-C reduction in secondary prevention: Real-world evidence from a homogeneous Spanish cohort with

Victoria Piro1, Elena Fuente2, Francisco Romano2

  • 1Department of Cardiology and Cardiac Rehabilitation, Hospital Universitario de Gran Canaria Dr Negrín, Las Palmas de Gran Canaria, Spain.

Clinica E Investigacion En Arteriosclerosis : Publicacion Oficial De La Sociedad Espanola De Arteriosclerosis
|June 5, 2026
PubMed

Insights

Inclisiran significantly lowered LDL-C by 63.8% in 90 days for secondary prevention patients. This real-world study highlights its effectiveness, especially when combined with statins, supporting its use in cardiovascular therapy.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Lipidology

Background:

  • Inclisiran demonstrates sustained low-density lipoprotein cholesterol (LDL-C) reduction in clinical trials.
  • Limited real-world data exists for inclisiran in homogeneous secondary prevention populations.
  • Coronary artery disease patients require effective lipid-lowering strategies.

Purpose of the Study:

  • To assess the early impact of inclisiran on LDL-C levels.
  • To evaluate inclisiran's efficacy in a real-world cohort of secondary prevention patients with coronary artery disease.

Main Methods:

  • Retrospective observational study of 120 adults with established atherosclerotic cardiovascular disease.
  • Comparison of lipid profiles at baseline and 90 days post-inclisiran treatment.
  • Subgroup analyses included sex, diabetes status, concomitant lipid-lowering therapies, Lp(a), and remnant cholesterol (RC).

Main Results:

  • Mean LDL-C decreased from 126.1 mg/dL to 45.3 mg/dL at 90 days, a 63.8% reduction.
  • 64.5% of patients achieved the therapeutic target of <55 mg/dL LDL-C.
  • Significant LDL-C reduction was observed with concurrent statin use (p<0.01); RC levels decreased by 16.6% (p=0.008).

Conclusions:

  • Inclisiran achieved substantial LDL-C reduction within 90 days in a real-world secondary prevention setting.
  • Concurrent statin therapy enhanced inclisiran's LDL-C lowering effect.
  • The favorable safety profile and dosing schedule support inclisiran's integration into guideline-directed cardiovascular therapy.
Abstract

Keywords:
Bempedoic acidCoronary artery diseaseEnfermedad arterial coronariaEstatinasEvidencia en práctica realEzetimibaEzetimibeInclisiranInclisiránLDL-CPrevención secundariaReal-world evidenceSecondary preventionStatinsc-LDLÁcido bempedoico

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...